Lymphoma-CLL/SLL

Primary Site Histology Behavior
C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809 9823 <Any value>
C700-C729, C751-C753 9823 3

Notes

9823 (EXCEPT C441, C690, C695-C696) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schema for the listed primary sites * C441, C690, C695-C696 (9823): *Lymphoma Ocular Adnexa* **Note 3:** Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) is always staged as a lymphoma. **Note 4:** The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 5:** In addition to coding EOD Primary Tumor, the following data items are also needed to assign a stage group for CLL/SLL. * Adenopathy * Anemia * Lymphocytosis * Organomegaly * Thrombocytopenia

Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Year of Diagnosis <BLANK> No NAACCR #390 None
Primary Site <BLANK> Yes NAACCR #400 None
Histology <BLANK> Yes NAACCR #522 None
Behavior <BLANK> Yes NAACCR #523 None
Tumor Size Clinical 999 No NAACCR #752 None
Tumor Size Pathological 999 No NAACCR #754 None
Tumor Size Summary 999 No NAACCR #756 None
Regional Nodes Positive 99 No NAACCR #820 None
Regional Nodes Examined 99 No NAACCR #830 None
LVI 8 No NAACCR #1182 None
EOD Primary Tumor 999 Yes NAACCR #772 None
EOD Regional Nodes 888 Yes NAACCR #774 None
EOD Mets 88 Yes NAACCR #776 None
SS2018 <BLANK> No NAACCR #764 None
Grade Clinical 8 No NAACCR #3843 CCCR/Canada
COC
NPCR
SEER		 SSDI
Grade Pathological 8 No NAACCR #3844 CCCR/Canada
COC
NPCR
SEER		 SSDI
Grade Post Therapy <BLANK> No NAACCR #3845 CCCR/Canada
COC
NPCR
SEER		 SSDI
B Symptoms 8 No NAACCR #3812 CCCR/Canada
COC
SEER		 SSDI
HIV Status 8 No NAACCR #3859 COC
SEER		 SSDI
NCCN International Prognostic Index (IPI) X8 No NAACCR #3896 COC
SEER		 SSDI
Adenopathy 9 No NAACCR #3804 CCCR/Canada
COC
SEER		 SSDI
Organomegaly 9 No NAACCR #3907 CCCR/Canada
COC
SEER		 SSDI
Anemia 9 No NAACCR #3811 CCCR/Canada
COC
SEER		 SSDI
Lymphocytosis 9 No NAACCR #3885 CCCR/Canada
COC
SEER		 SSDI
Thrombocytopenia 9 No NAACCR #3933 CCCR/Canada
COC
SEER		 SSDI

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context
eod_2018_stage_group = 90

Next Step

  2. EOD Primary Tumor
  3. ss2018_t

Next Step

  2. EOD Regional Nodes
  3. ss2018_n

Next Step

  2. EOD Mets
  3. ss2018_m

Next Step

  2. Summary Stage - T only
  3. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00795 NAACCR #3800
None 		None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
None 		None